Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Blood

Volumn 120, Issue 16, 2012, Pages 3222-3228

  Benevolo, Giulia ^a   Stacchini, Alessandra ^b   Spina, Michele ^c   Ferreri, Andrés J M ^d   Arras, Marcella ^e   Bellio, Laura ^d   Botto, Barbara ^a   Bulian, Pietro ^c   Cantonetti, Maria ^f   Depaoli, Lorella ^g   Di Renzo, Nicola ^h   Di Rocco, Alice ⁱ   Evangelista, Andrea ^a   Franceschetti, Silvia ^j   Godio, Laura ^b   Mannelli, Francesco ^k   Pavone, Vincenzo ^l   Pioltelli, Pietro ^m   Vitolo, Umberto ^a   Pogliani, Enrico M ^m  

^a Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

^b Pathology Institute University   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e Haematology Division   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Haematology Division   (Italy)

^h Haematology Division   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^k UNIVERSITY OF FLORENCE   (Italy)

^l Haematology Division   (Italy)

^m Haematology Institute University   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BLASTOID VARIANT OF MANTLE CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID FLOW; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT;

EID: 84868128326     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-423095     Document Type: Article

References (41)

1. Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2005;19(4):597-609. (Pubitemid 41096708)
2. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate grade and immunoblastic lymphoma. Blood. 1998;91(4):1178-1184. (Pubitemid 28086870)
3. Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol. 2000;11(6):685-690.
4. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157. (Pubitemid 46152515)
5. Hollender A, Kvaloy S, Nome O, et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13(7):1099-1107.
6. Barosi G, Carella A, et al. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica. 2006;91(1):96-103. (Pubitemid 43235392)
7. Glass JP, Melamed M, Chemik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369-1375. (Pubitemid 9256272)
8. Ward MS. The use of flow cytometry in the diagnosis and monitoring of malignant haematological disorders. Pathology. 1999;31(4):382-392. (Pubitemid 30009101)
9. French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol. 2000;23(6):369-374.
10. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68(20):1674-1679. (Pubitemid 46763254)
11. Dux R, Kindler-Rohrborn A, Annas M, et al. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci. 1994;121(1):74-78.
12. Hegde U, Filie AC, Little R, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502. (Pubitemid 40070727)
13. Quijano S, Lòpez A, Sancho JM, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462-1469.
14. Stacchini A, Aliberti A, Demurtas A, et al. Ten antibodies, six colors, twelve parameters: a multiparameter flow cytometric approach to evaluate leptomeningeal disease in B-cell non-Hodgkin lymphomas. Cytometry B Clin Cytom. 2012;82(3):139-144.
15. Alvarez R, Dupuis J, Plonquet A, et al. Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma. Ann Oncol. 2012;23(5):1274-1279.
16. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
17. Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381-385.
18. Ladetto M, De Marco F, Benedetti F, Vitolo U, et al. from Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicentre randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-4013.
19. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol. 2012;2012:735392.
20. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
21. Gray R. A class of k-sample test for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988;16:1141-1154.
22. Fine P, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-506.
23. Zucca E, Conconi A, Mughal T, et al. Patterns of outcome and prognostic factors in primary largecell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27.
24. Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diff use large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-1457.
25. Avilés A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology. 2005;69(3):256-260. (Pubitemid 41433584)
26. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331.
27. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol. 2005;131(1):13-21. (Pubitemid 43899703)
28. Subirá D, Castanon S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol. 2002;117(6):952-958. (Pubitemid 34564353)
29. Finn WG, Peterson LC, James C, et al: Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol. 1998;110(3):341-346. (Pubitemid 28406992)
30. Roma AA, Garcia A, Avagnina A, et al. Lymphoid and myeloid neoplasms involving cerebrospinal fluid: Comparison of morphologic examination and immunophenotyping by flow cytometry. Diagn Cytopathol. 2002;27(5):271-275. (Pubitemid 35278818)
31. Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-1093. (Pubitemid 351213386)
32. Kim SJ, Oh SY, Kim JS, Kim H, et al. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemmal. Ann Hematol. 2011;90(5):539-546.
33. Sancho JM, Orfao A, Quijano S, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol. 2010;85(4):321-328.
34. Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom? Blood Rev. 2012;26(3):97-106.
35. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggresssive B-cell lymphoma: an analysis of patients treated on the Mabthera International trial and trials of the German high-grade non-Hodgkin lymphoma study group. Ann Oncol. 2012;23(5):1267-1273.
36. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
37. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
38. + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
39. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033. (Pubitemid 46224009)
40. Gökbuget N, Hartog CM, Bassan R. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma. Haematologica. 2011;96(2):238-244.
41. Abramson JS, Hellmann M, Barnes JA, et al.Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 2010;116(18):4283-4290.